AU762827B2 - Antibiotic compositions for treatment of the eye, ear and nose - Google Patents

Antibiotic compositions for treatment of the eye, ear and nose Download PDF

Info

Publication number
AU762827B2
AU762827B2 AU13101/00A AU1310100A AU762827B2 AU 762827 B2 AU762827 B2 AU 762827B2 AU 13101/00 A AU13101/00 A AU 13101/00A AU 1310100 A AU1310100 A AU 1310100A AU 762827 B2 AU762827 B2 AU 762827B2
Authority
AU
Australia
Prior art keywords
inflammatory agent
agent comprises
dexamethasone
ophthalmic
steroidal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU13101/00A
Other languages
English (en)
Other versions
AU1310100A (en
Inventor
Robert L. Abshire
Gerald Cagle
David W. Stroman
John M. Yanni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26799441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU762827(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of AU1310100A publication Critical patent/AU1310100A/en
Application granted granted Critical
Publication of AU762827B2 publication Critical patent/AU762827B2/en
Priority to AU2003248033A priority Critical patent/AU2003248033B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU13101/00A 1998-09-30 1999-09-29 Antibiotic compositions for treatment of the eye, ear and nose Expired AU762827B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003248033A AU2003248033B2 (en) 1998-09-30 2003-09-15 Antibiotic Compositions for Treatment of the Eye, Ear and Nose

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10250498P 1998-09-30 1998-09-30
US10250698P 1998-09-30 1998-09-30
US60/102504 1998-09-30
US60/102506 1998-09-30
PCT/US1999/022622 WO2000018386A2 (en) 1998-09-30 1999-09-29 Antibiotic compositions for treatment of the eye, ear and nose

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003248033A Division AU2003248033B2 (en) 1998-09-30 2003-09-15 Antibiotic Compositions for Treatment of the Eye, Ear and Nose

Publications (2)

Publication Number Publication Date
AU1310100A AU1310100A (en) 2000-04-17
AU762827B2 true AU762827B2 (en) 2003-07-03

Family

ID=26799441

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13101/00A Expired AU762827B2 (en) 1998-09-30 1999-09-29 Antibiotic compositions for treatment of the eye, ear and nose

Country Status (18)

Country Link
EP (5) EP1117401B1 (en:Method)
JP (5) JP2002525317A (en:Method)
KR (1) KR101463243B1 (en:Method)
CN (2) CN100374114C (en:Method)
AR (2) AR020661A1 (en:Method)
AT (2) ATE501732T1 (en:Method)
AU (1) AU762827B2 (en:Method)
BR (1) BRPI9914151B1 (en:Method)
CA (3) CA2774207A1 (en:Method)
CY (3) CY1111404T1 (en:Method)
DE (2) DE69912972T2 (en:Method)
DK (5) DK1384478T3 (en:Method)
ES (4) ES2526521T3 (en:Method)
HK (1) HK1038691B (en:Method)
PT (5) PT1117401E (en:Method)
TR (2) TR200704370T2 (en:Method)
TW (1) TWI222361B (en:Method)
WO (1) WO2000018386A2 (en:Method)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
DE19937115A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
KR100722502B1 (ko) 1999-09-24 2007-05-28 알콘, 인코퍼레이티드 사이프로플록사신 및 덱사메타손 함유 국소용 현탁제
DE19962470A1 (de) * 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
AU2001261748A1 (en) * 2000-05-19 2001-12-03 Alcon Laboratories Inc. Antibiotic compositions for treatment of the eye, ear and nose
AU2001276928A1 (en) 2000-07-26 2002-02-05 Alcon Universal Ltd. Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
JPWO2002040028A1 (ja) * 2000-11-16 2004-03-18 わかもと製薬株式会社 抗菌ゲル化点眼剤
WO2002049633A2 (en) 2000-12-20 2002-06-27 Alcon, Inc. Use of amidoamines to treat or prevent acanthamoeba and fungal infections
AU2002226926A1 (en) * 2000-12-20 2002-07-01 Alcon, Inc. Antifungal compositions containing an antibiotic and one or more amidoamines
AU2002333671B2 (en) 2001-09-21 2006-07-20 Novartis Ag Method of treating middle ear infections
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US7514451B2 (en) 2003-09-10 2009-04-07 Kyorin Pharmaceutical Co., Ltd. 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
EP1784164A4 (en) * 2004-09-03 2008-07-09 Piedmont Pharmaceuticals Llc PROCESS FOR TRANSMEMBRANE TREATMENT AND PREVENTION OF OTITIS MEDIA
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
AU2005317228A1 (en) * 2004-12-10 2006-06-22 Alcon, Inc. Compositions for treatment of ear infections
CN101317847B (zh) * 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
TWI544934B (zh) * 2008-06-09 2016-08-11 愛爾康研究有限公司 含有氟喹諾酮抗生素藥物之經改良藥學組成物
CN102470139A (zh) * 2009-07-02 2012-05-23 爱尔康研究有限公司 用于治疗眼、耳或鼻感染的包含非那沙星的组合物和方法
CA2786525A1 (en) * 2010-01-07 2011-07-14 Regents Of The University Of Minnesota Methods and compositions for applying moxifloxacin to the ear
RU2014127492A (ru) 2011-12-06 2016-02-10 Алькон Рисерч, Лтд. Композиции целлюлозного геля с улучшенной стабильностью вязкости
RU2472507C1 (ru) * 2012-02-01 2013-01-20 Закрытое акционерное общество "Брынцалов-А" Водный состав на основе моксифлоксацина для парентерального введения
US9504691B2 (en) 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
CN104224802B (zh) * 2014-09-19 2017-12-12 南京优科生物医药研究有限公司 一种盐酸莫西沙星滴耳剂及其制备方法
RU2595837C2 (ru) * 2014-09-29 2016-08-27 Открытое Акционерное Общество "Татхимфармпрепараты" Состав и способ получения глазных капель
EP3369422A4 (en) * 2015-10-29 2018-12-05 Teika Pharmaceutical Co., Ltd. External preparation
WO2019193513A1 (en) * 2018-04-03 2019-10-10 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica
GB2613469A (en) * 2020-06-10 2023-06-07 Ocular Science Inc Compositions and uses in method for post-operative ocular care
CN116270662A (zh) * 2021-12-03 2023-06-23 苏州欧康维视生物科技有限公司 盐酸莫西沙星地塞米松磷酸钠滴眼液
KR102656260B1 (ko) 2022-10-14 2024-04-09 주식회사태준제약 목시플록사신을 포함하는 안과용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607942A (en) * 1988-07-15 1997-03-04 Bayer Aktiengesellschaft 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223493A (en) 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
WO1990001933A1 (en) * 1988-08-26 1990-03-08 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
JPH085779B2 (ja) * 1989-09-22 1996-01-24 杏林製薬株式会社 フレロキサシン点眼液
JPH03109236A (ja) * 1989-09-22 1991-05-09 Hoya Corp 半導体超微粒子分散ガラスの製造方法
TW209865B (en:Method) * 1992-01-10 1993-07-21 Bayer Ag
CA2132826C (en) 1992-05-06 1999-01-05 Masood Chowhan Use of borate-polyol complexes in ophthalmic compositions
DE4424369A1 (de) * 1994-07-11 1996-01-18 Bayer Ag Pyrido[3,2,1.i,j][3,1]benzoxazinderivate
JPH0892241A (ja) * 1994-09-22 1996-04-09 Ss Pharmaceut Co Ltd ５−ヒドラジノキノロンカルボン酸誘導体及びこれを有効成分とする抗菌剤
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
IL120317A (en) * 1995-06-06 2000-08-13 Bayer Ag Ciprofloxacin-hydrocortisone suspension
JP3290914B2 (ja) * 1997-03-17 2002-06-10 参天製薬株式会社 眼組織におけるキノロン系抗菌剤の定量装置
AU731693B2 (en) * 1997-09-25 2001-04-05 Bayer Intellectual Property Gmbh Drug formulation having controlled release of active compound
WO2000016736A1 (en) 1998-09-23 2000-03-30 Unilever N.V. Oral care compositions
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US20020001617A1 (en) * 2000-05-26 2002-01-03 Chang-Hyun Lee Rapidly disintegrating tablet and process for the manufacture thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607942A (en) * 1988-07-15 1997-03-04 Bayer Aktiengesellschaft 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives

Also Published As

Publication number Publication date
CY1115916T1 (el) 2017-01-25
HK1038691B (en) 2004-04-23
EP2269602A1 (en) 2011-01-05
PT1384478E (pt) 2011-05-12
EP2301541B1 (en) 2014-08-20
CN1650863A (zh) 2005-08-10
DK2301541T3 (da) 2014-09-01
JP2013018799A (ja) 2013-01-31
CA2774207A1 (en) 2000-04-06
EP1117401B1 (en) 2003-11-19
EP2301541A1 (en) 2011-03-30
BRPI9914151B1 (pt) 2017-10-03
HK1059572A1 (en) 2004-07-09
HK1150769A1 (en) 2012-01-13
AR081393A2 (es) 2012-08-29
ES2519190T3 (es) 2014-11-06
WO2000018386A3 (en) 2000-06-08
HK1150756A1 (en) 2012-01-13
EP2796138B1 (en) 2016-08-17
DE69943287D1 (de) 2011-04-28
PT2796138T (pt) 2016-09-22
WO2000018386A2 (en) 2000-04-06
DK1117401T3 (da) 2004-02-23
JP2012067141A (ja) 2012-04-05
CN1320035A (zh) 2001-10-31
KR101463243B1 (ko) 2014-12-17
DK2269602T3 (en) 2014-12-15
JP5563041B2 (ja) 2014-07-30
BRPI9914151B8 (en:Method) 2021-05-25
CN1184968C (zh) 2005-01-19
CY1115759T1 (el) 2017-01-25
BR9914151A (pt) 2001-06-26
JP2009007375A (ja) 2009-01-15
DK2796138T3 (en) 2016-12-05
AR020661A1 (es) 2002-05-22
CA2659064A1 (en) 2000-04-06
CA2342211C (en) 2009-05-26
EP2796138A1 (en) 2014-10-29
PT2301541E (pt) 2014-10-29
HK1038691A1 (en) 2002-03-28
CN100374114C (zh) 2008-03-12
ES2602956T3 (es) 2017-02-23
TR200100883T2 (tr) 2001-10-22
ES2526521T3 (es) 2015-01-13
JP2014144982A (ja) 2014-08-14
DE69912972T2 (de) 2004-04-22
EP1384478A1 (en) 2004-01-28
EP2269602B1 (en) 2014-11-19
JP2002525317A (ja) 2002-08-13
TWI222361B (en) 2004-10-21
KR20010075138A (ko) 2001-08-09
ATE501732T1 (de) 2011-04-15
CY1111404T1 (el) 2015-08-05
PT2269602E (pt) 2014-12-29
ES2207307T3 (es) 2004-05-16
TR200704370T2 (tr) 2007-11-21
CA2342211A1 (en) 2000-04-06
EP1117401A2 (en) 2001-07-25
ATE254458T1 (de) 2003-12-15
DK1384478T3 (da) 2011-05-23
DE69912972D1 (de) 2003-12-24
PT1117401E (pt) 2004-03-31
AU1310100A (en) 2000-04-17
EP1384478B1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
AU762827B2 (en) Antibiotic compositions for treatment of the eye, ear and nose
US6716830B2 (en) Ophthalmic antibiotic compositions containing moxifloxacin
AU1310300A (en) Antibiotic compositions for treatment of the eye, ear and nose
EP1117406A1 (en) Antibiotic compositions for treatment of the eye, ear and nose
AU2003248033B2 (en) Antibiotic Compositions for Treatment of the Eye, Ear and Nose
ZA200101752B (en) Methods of treating or preventing ophthalmi infections with moxifloxacin.
HK1059572B (en) Antibiotic compositions containing moxifloxacin for treatment of the eye
HK1150769B (en) Antibiotic compositions for treatment of the eye
HK1150756B (en) Antibiotic compositions for treatment of the ear
AU2007201610A1 (en) Antibiotic compositions for treatment of the eye, ear and nose
MXPA01003293A (en) Antibiotic compositions for treatment of the eye, ear and nose
MXPA01003294A (en) Antibiotic compositions for treatment of the eye, ear and nose

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired